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INTRODUCTION: Clostridioides difficile infection (CDI) is common in patients with cirrhosis and is associated with poor
outcomes. CDI risk factors in this population have been well characterized; however, risk factors of
recurrent CDI (R-CDI) after treatment have not been explored. We sought to estimate the incidence of
R-CDI and its associated risk factors in patients with cirrhosis.
METHODS: We performed a cohort study of patients with cirrhosis hospitalized with CDI between 2012 and 2016.
We collected patient characteristics, including detailed information on the CDI, features of the
underlying liver disease, and outcomes including R-CDI, hospital readmission, and mortality. R-CDI
was defined as CDI occurring 2–8 weeks after the initial episode. Cox proportional hazards model was
used to identify variables independently associated with the outcomes.
RESULTS: A total of 257 hospitalized patients with cirrhosis and CDI were included. CDI was community
associated in 22.6%. The incidence of R-CDI was 11.9%. R-CDI was not significantly associated with
medications at hospital admission or discharge. Independent risk factors of R-CDI included increased
Charlson Comorbidity Index (hazard ratio [HR] 1.30; 95%confidence interval [CI]: 1.09–1.55) anduse
of lactulose (HR 2.58; 95% CI: 1.09–6.09). The 30-day readmission rate was 37%, and readmission
was associated with increased Charlson Comorbidity Index (HR 1.12; 95% CI: 1.03–1.23) and Model
for End-Stage Liver Disease score (HR 1.04; 95% CI: 1.01–1.07). The 90-day mortality was 22.8%.
DISCUSSION: In patients with cirrhosis, R-CDI is associated with comorbidity burden and lactulose use. Attention to
these factors might aid clinicians in efforts to prevent R-CDI and improve outcomes in this population.
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INTRODUCTION
Clostridioides difficile infection (CDI) is a common diarrheal
pathogen with increasing incidence and severity in both out-
patient and inpatient settings (1,2). Despite significant advances
in CDI detection and treatment, the resultant healthcare costs
continue to rise, and outcomes continue to worsen (3,4). Com-
mon CDI risk factors include hospitalization, immunosuppres-
sion, advanced comorbidities, and the use of medications such as
antibiotics and proton pump inhibitors (5). These risk factors are
highly prevalent in patients with liver cirrhosis, who are partic-
ularly vulnerable to CDI. Patients with cirrhosis have high rates of
hospitalization and are often exposed to antibiotics for pro-
phylaxis and treatment of frequent infections (6,7).
Traditional first-line therapeutic agents for CDI include
metronidazole and oral vancomycin, with response rates ranging
from 65% to 98% depending on disease severity (8,9). However,
recent updates to clinical practice guidelines no longer endorse
metronidazole and, instead, suggest either oral vancomycin or
fidaxomicin as first-line therapy for both severe and nonsevere
cases. This change was based on improved symptom response
and mortality with vancomycin when compared with metroni-
dazole (10,11). Treatment failure remains a major concern; re-
current CDI (R-CDI) results in increased hospital length of stay,
readmissions, and costs (12). These poor outcomes are magnified
in patients with cirrhosis. For the general population hospitalized
with CDI, average length of stay is 13 days, inpatient mortality is
8%, and 30-day readmissions occur in 20%; in patients with cir-
rhosis, these figures are significantly higher: at 14 days, 14%, and
35%, respectively (8,12,13). In patients with cirrhosis, CDI is also
an independent risk factor of mortality, similar to other cirrhosis
complications such as hepatic encephalopathy, variceal hemor-
rhage, and spontaneous bacterial peritonitis. Despite this growing
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evidence for identifying risk factors of CDI and outcomes in
cirrhosis, there remains a gap in the literature exploring risk
factors of R-CDI in this population.
We, therefore, sought to identify risk factors of R-CDI and its
associated outcomes in patients with cirrhosis andCDI. To achieve
this goal, we performed a cohort study of hospitalized patients with
cirrhosis and CDI between 2012 and 2016, examining clinical
characteristics and outcomes during and after hospitalization.
METHODS
Study design and patients
The study protocol was approved by the Indiana University In-
stitutional Review Board. We performed a retrospective cohort
study of adult patients (aged $18 years) admitted to Indiana
University Hospital between January 1, 2012, and December 31,
2016, with a diagnosis of cirrhosis and CDI. Indiana University
Hospital is a tertiary referral center and the only liver transplant
program in the state. Patientswere followedup for 90days fromthe
time of the CDI diagnosis to ascertain outcomes. The electronic
medical record was screened for hospitalized patients with both
diagnoses using diagnostic codes for each condition and positive
laboratory results for CDI (a rapid membrane enzyme immuno-
assay for the simultaneous detection of C. difficile glutamate de-
hydrogenase antigen and toxins A and B in a single reaction).
Patients identified in this way were then manually reviewed
to confirm the diagnoses. We also required patients to have
compatible symptoms (i.e., patients with a positive laboratory result
without diarrhea or other clinical features of CDI were not in-
cluded). To prevent false positive results at our hospital, laboratory
policy mandates that all laxatives (including lactulose) must be
stopped at least 48 hours before CDI testing. Cirrhosis was con-
firmed by liver histology or on the basis of compatible clinical,
laboratory, and imagingfindings.CDIwas confirmedon thebasis of
compatible symptoms and a positive stool toxin enzyme immu-
noassay or polymerase chain reaction. We excluded patients with
previous CDI, those on treatment for CDI before admission, those
hospitalized ,48 hours, those with inflammatory bowel disease,
and those with previous liver transplants.
Outcomes
Theprimary study outcomewasR-CDI, defined asCDI occurring
within 14–56 days of the initial CDI diagnosis date (14). As in the
inclusion criteria for initial CDI, R-CDI was defined based on
compatible symptoms accompanied by a positive laboratory test.
Secondary outcomes included mortality within 90 days of CDI
diagnosis and readmissions within 30 days of hospital discharge.
Variables
We collected multiple variables that could be associated with
patient outcomes. These variables included demographic in-
formation (age, sex, and race) and medical history (body mass
index, liver disease etiology, Charlson Comorbidity Index (15),
active alcohol use, presence of end-stage renal disease, and
presence of concurrent infections (16)). We also collected
measures of liver disease severity on admission (Child–Pugh
score (17), Model for End-Stage Liver Disease [MELD] score
(18)) and cirrhosis complications (previous transjugular intra-
hepatic shunt, hepatocellular carcinoma, and spontaneous bac-
terial peritonitis). Medications of interest on admission and at
discharge included proton pump inhibitors, histamine 2 receptor
antagonists, antibiotics, nonselective b-blockers, lactulose, pro-
biotics, and polyethylene glycol 3350. Index hospitalization data
included the primary reason for admission, admission to in-
tensive care, length of stay, and discharge disposition. Charac-
teristics of the initial CDI included the type of CDI (community-
associated; community-onset, healthcare facility-associated; and
healthcare facility-onset CDI) (14), presence of severe or fulmi-
nant CDI, and CDI treatment. Severe and fulminant CDI were
defined based on standard guideline definitions (14). For those
with R-CDI, characteristics of the recurrence were also captured.
Statistical analysis
Categorical variables were described using counts and percen-
tages; continuous variables were described with means and SDs
for normally distributed variables and with medians and inter-
quartile ranges for nonnormally distributed variables. Because
R-CDI is defined as occurring within 2–8 weeks of the initial CDI,
for the primary R-CDI analysis, we excluded those who died
within 2weeks of the initial CDI and thosewithout follow-up data
beyond the initial 2 weeks. For the readmission analysis, we ex-
cluded those without follow-up data after discharge. Days to the
outcome occurrence were examined using the Kaplan–Meier
curve. The univariable associations between patient character-
istics and outcome were evaluated using the Cox proportional
hazards model. Firth bias correction method was used to address
the monotone likelihood issue where parameter estimates con-
verges to infinite because of small sample size and sparse data
Figure1.Flowdiagram. The sumof the exclusion criteria is greater than the
total number of patients excluded because some patients fulfilled multiple
exclusion criteria. CDI, Clostridioides difficile infection.





(19). Multivariable analysis was performed in which all patient
characteristics with a univariable P , 0.25 were subjected to
a forward stepwise variable selection process. A 2-sided P, 0.05
was considered significant. All statistical analyses were performed
using SAS version 9.4 (The SAS institute, Cary, NC).
RESULTS
Baseline characteristics
Of 630 patients identified as having a diagnosis of cirrhosis and
a hospitalization with CDI during the study period, 373 were
excluded, leaving 257 patients for analysis (Figure 1). Patient
Table 1. Patient characteristics (N 5 257)
Characteristic Value
Age, yr, mean (SD) 58.5 (12.3)
Male sex, % 52.9
Caucasian race, % 84.8













Severe CDI, % 62.6




Charlson Comorbidity Index, median (IQR) 6 (4–7)
Active alcohol use, % 25.3
End-stage renal disease, % 5.4
Concurrent infection, % 39.3





MELD, median (IQR) 18 (12–24)
Previous TIPS, % 6.6
Hepatocellular carcinoma, % 8.2
Previous spontaneous bacterial peritonitis, % 18.7
Admission medications, %







Polyethylene glycol 3350 3.9







Acute kidney injury/electrolyte abnormality 8.2
Elective procedure/surgery 2.7
Other 10.9
Intensive care, % 30.7






CDI, Clostridioides difficile infection; IQR, interquartile range; MELD, Model for
End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; TIPS,
transjugular intrahepatic portosystemic shunt.
Figure 2. Kaplan–Meier plot of time to CDI recurrence. Patients were
followedup from the timeof initial CDI diagnosis. CDI,Clostridioides difficile
infection.
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Age, per year 1.04 (1.00, 1.07)
Sex
Men 13.9 1.00
Women 7.0 0.50 (0.20–1.23)
Race
Caucasian 11.7 1.00
Other 3.4 0.28 (0.04–2.07)
Body mass index, per 1 kg/m2 1.02 (0.97–1.08)
Cirrhosis etiology
Alcohol 13.6 1.00
Hepatitis C 3.1 0.21 (0.04–0.99)
NASH 18.0 1.36 (0.52–3.52)






Healthcare facility-onset 7.6 1.25 (0.32–4.84)
Indeterminate 0 0.42 (0.02–9.21)
Severe CDI
No 10.0 1.00
Yes 11.0 1.28 (0.55–2.99)
Fulminant CDI
No 11.3 1.00
Yes 4.5 0.49 (0.07–3.61)
CDI treatment
Metronidazole only 10.2 1.00
Vancomycin 6metronidazole 11.0 1.19 (0.52–2.75)
Charlson Comorbidity Index, per 1 unit 1.25 (1.05–1.47) 1.30 (1.09–1.55)
Active alcohol use
No 11.2 1.00
Yes 8.9 0.79 (0.29–2.14)
End-stage renal disease
No 9.7 1.00
Yes 25.0 2.73 (0.81–9.23)
Concurrent infection
No 10.6 1.00
Yes 10.5 0.95 (0.40–2.27)
Child–Pugh score, per 1 unit 1.01 (0.85, 1.21)
Child–Pugh
A 15.8 1.00
B 7.0 0.40 (0.10, 1.61)
C 12.6 0.84 (0.24, 2.96)












MELD, per 1 unit 1.02 (0.97, 1.08)
Previous TIPS
No 10.2 1.00
Yes 16.7 2.14 (0.50–9.14)
Hepatocellular carcinoma
No 11.5 1.00
Yes 0 0.28 (0.02–4.97)
Previous spontaneous bacterial peritonitis
No 8.7 1.00
Yes 19.4 2.28 (0.93–5.60)
Proton pump inhibitor
No 8.7 1.00
Yes 12.1 1.33 (0.56–3.16)
H2 blocker
No 9.7 1.00
Yes 23.1 2.59 (0.77–8.76)
Rifaximin
No 8.2 1.00
Yes 18.0 2.28 (0.97–5.33)
Fluoroquinolones
No 9.1 1.00
Yes 18.2 2.05 (0.80–5.25)
b-blockers
No 8.0 1.00
Yes 15.5 1.94 (0.84–4.48)
Lactulose
No 8.0 1.00 1.00
Yes 15.5 2.08 (0.90–4.80) 2.58 (1.09–6.09)
Probiotics
No 10.1 1.00
Yes 20.0 2.14 (0.50–9.15)
Polyethylene glycol 3350
No 11.0 1.00
Yes 0 0.52 (0.03–9.17)
Intensive care
No 11.9 1.00
Yes 6.1 0.61 (0.18–2.05)
Length of stay, per day 1.02 (1.00–1.05)
Discharge disposition
Home 6.6 1.00
Hospice 0 2.10 (0.10–43.47)
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characteristics are summarized in Table 1. Themean age was 58.5
years (SD 12.3), and 52.9%weremen; 91.8% had Child-Pugh B or
C cirrhosis, and the median MELD was 18 (interquartile range
12–24). The most common admission medications were proton
pump inhibitors (55.6%), nonselective b-blockers (33.1%), lac-
tulose (35.4%), and rifaximin (24.9%). Approximately 15% were
taking fluoroquinolones. CDI was classified as healthcare facility-
onset CDI in 40.9%; community-onset, healthcare facility-
associated CDI in 29.6%; and community-associated CDI in
22.6%. CDI was severe in 62.6%; 51.4% received vancomycin, and
48.6% received metronidazole only. One patient received fidax-
omicin, and 1 received fecal microbiota transplant.
Recurrent CDI
Of the 257 patients, 28 died within 2 weeks, and 21 did not have
follow-up data beyond 2weeks, leaving 208 for analysis of R-CDI.
A total of 22 patients developed R-CDI, resulting in an estimated
R-CDI incidence of 11.9% (Figure 2). Univariable associations
between admission factors and R-CDI are tabulated in Table 2.
R-CDI was associated with increased age, nonhepatitis C etiology
of cirrhosis, increased Charlson Comorbidity Index, increased
length of hospital stay, and discharge to “other” location. There
were no significant associations between R-CDI and medications
at hospital admission or discharge. At discharge, 62% of patients
were taking a proton pump inhibitor, with 14.5% R-CDI (com-
pared with 7.6% in those not taking a proton pump inhibitor; P5
0.15). In addition, 12% were taking a fluoroquinolone at dis-
charge, with 21.8% R-CDI (compared with 10.7% in those not
taking a fluoroquinolone; P5 0.18). CDI recurred in the patient
who received fidaxomicin and in the patient who received fecal
microbiota transplant. In amultivariablemodel, stepwise variable
selection identified 2 variables independently associated with R-
CDI. A greater risk of R-CDI was associated with the use of
lactulose (hazard ratio [HR] 2.58; 95% confidence interval [CI]:
1.09–6.09) and increased Charlson Comorbidity Index, where
each point increase in the comorbidity index was associated with
30% greater hazard of R-CDI (HR 1.30; 95% CI: 1.09–1.55).
Among the 22 patients who developed R-CDI, 9 (40.9%) met
criteria for severe CDI, and 1 patient developed fulminant colitis
but was felt to be too ill for surgery and, thus, did not undergo
colectomy; this patient died during the admission. Five patients
(22.7%) required intensive care. For the recurrence, 4 patients
received oral metronidazole only, 11 received oral vancomycin
only, 3 received intravenous metronidazole only, 1 received oral
fidaxomicin, and the remaining 3 received combination therapy.
None received fecal microbiota transplant. Five patients (22.7%)
died or enrolled in hospice care. Twelve of the 22 patients had








Died 0 5.52 (0.24–127.05)
Other 22.8 4.07 (1.71–9.67)
CDI,Clostridioides difficile infection; CI, confidence interval; MELD,Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; TIPS, transjugular intrahepatic
portosystemic shunt.
Figure3. (a) Kaplan–Meier plot of time to hospital readmission. Patientswere followedup from the time of index hospital discharge. (b) Kaplan–Meier plot of
time to death. Patients were followed up from the time of initial Clostridioides difficile infection diagnosis.





Table 3. Univariable associations with 30-day readmission and 90-day mortality
30-day readmission, % Hazard ratio (95% CI) 90-day mortality, % Hazard ratio (95% CI)
Age, per year 1.01 (0.99–1.03) 1.00 (0.98–1.02)
Sex
Men 33.0 1.00 22.1 1.00
Women 39.8 1.23 (0.78–1.94) 19.0 0.83 (0.48–1.43)
Race
Caucasian 37.5 1.00 19.7 1.00
Other 28.6 0.72 (0.35–1.50) 25.6 1.39 (0.70–2.76)
Body mass index, per 1 kg/m2 1.00 (0.96–1.03) 0.99 (0.95–1.03)
Cirrhosis etiology
Alcohol 31.0 1.00 27.1 1.00
Hepatitis C 28.8 0.88 (0.46–1.68) 17.6 0.67 (0.34–1.32)
NASH 45.8 1.52 (0.81–2.83) 8.8 0.31 (0.11–0.82)
Other 46.9 1.65 (0.83–3.28) 31.1 1.24 (0.62–2.47)
CDI type
Community-associated 32.1 1.00 19.0 1.00
Community-onset, healthcare facility-
associated
43.3 1.43 (0.78–2.64) 17.1 0.97 (0.43–2.15)
Healthcare facility-onset 36.8 1.19 (0.65–2.17) 25.7 1.52 (0.75–3.07)
Indeterminate 20.0 0.55 (0.16–1.86) 11.1 0.58 (0.13–2.63)
Severe CDI
No 28.6 1.00 11.5 1.00
Yes 42.5 1.67 (1.04–2.69) 26.1 2.88 (1.48–5.59)
Fulminant CDI
No 35.8 1.00 17.0 1.00
Yes 41.2 1.15 (0.53–2.51) 45.5 3.48 (1.91–6.35)
CDI treatment
Metronidazole only 37.8 1.00 16.0 1.00
Vancomycin6 metronidazole 34.4 0.90 (0.57–1.43) 25.0 1.81 (1.04–3.15)
Charlson Comorbidity Index, per 1 unit 1.11 (1.02–1.21) 1.00 (0.89–1.12)
Active alcohol use
No 38.3 1.00 19.3 1.00
Yes 30.9 0.78 (0.45–1.34) 24.6 1.21 (0.68–2.18)
End-stage renal disease
No 34.9 1.00 21.0 1.00
Yes 58.3 1.99 (0.91–4.34) 14.3 0.66 (0.16–2.71)
Concurrent infection
No 34.9 1.00 22.4 1.00
Yes 38.7 1.08 (0.68–1.73) 17.8 0.84 (0.48–1.49)
Child–Pugh score, per 1 unit 1.05 (0.96–1.16) 1.27 (1.12–1.42)
Child–Pugh
A 26.3 1.00 14.3 1.00
B 34.1 1.40 (0.54–3.60) 11.2 0.77 (0.21–2.76)
C 40.2 1.74 (0.68–4.40) 28.3 2.31 (0.71–7.47)
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Table 3. (continued)
30-day readmission, % Hazard ratio (95% CI) 90-day mortality, % Hazard ratio (95% CI)
MELD, per 1 unit 1.03 (1.00–1.07) 1.08 (1.04–1.11)
Previous TIPS
No 36.3 1.00 20.0 1.00
Yes 36.4 1.03 (0.38–2.83) 29.4 1.74 (0.69–4.37)
Hepatocellular carcinoma
No 36.4 1.00 21.2 1.00
Yes 35.3 0.99 (0.43–2.28) 14.3 0.74 (0.23–2.36)
Previous spontaneous bacterial peritonitis
No 34.1 1.00 20.6 1.00
Yes 47.1 1.47 (0.85, 2.56) 20.8 1.07 (0.54, 2.13)
Proton pump inhibitor
No 34.5 1.00 19.3 1.00
Yes 37.6 1.10 (0.69–1.76) 21.7 1.11 (0.64–1.92)
H2 blocker
No 35.6 1.00 21.0 1.00
Yes 46.2 1.31 (0.57–3.02) 14.3 0.62 (0.15–2.56)
Rifaximin
No 35.3 1.00 19.7 1.00
Yes 39.6 1.11 (0.66–1.86) 23.4 1.21 (0.67–2.20)
Fluoroquinolones
No 32.7 1.00 19.3 1.00
Yes 54.5 1.83 (1.07–3.11) 28.2 1.40 (0.72–2.71)
b-blockers
No 36.0 1.00 19.8 1.00
Yes 36.8 0.98 (0.60–1.58) 22.4 1.10 (0.63–1.92)
Lactulose
No 31.9 1.00 17.5 1.00
Yes 44.9 1.51 (0.95–2.40) 26.4 1.58 (0.92–2.71)
Probiotics
No 36.3 1.00 20.5 1.00
Yes 36.4 1.04 (0.38–2.85) 23.1 1.14 (0.36–3.66)
Polyethylene glycol 3350
No 37.2 1.00 21.1 1.00
Yes 12.5 0.29 (0.04–2.10) 10.0 0.49 (0.07–3.55)
Intensive care
No 37.4 1.00 11.2 1.00
Yes 31.7 0.85 (0.46–1.54) 41.8 5.16 (2.95–9.02)
Length of stay, per day 1.02 (1.00–1.04) 1.01 (0.99–1.03)
Discharge disposition
Home 37.7 1.00 9.2 1.00
Hospice 0 0.18 (0.01–2.92) 25.0 12.20 (4.22–35.26)
Died — — — —
Other 37.9 1.03 (0.63–1.70) 10.3 1.42 (0.57–3.53)
CDI,Clostridioides difficile infection; CI, confidence interval; MELD,Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; TIPS, transjugular intrahepatic
portosystemic shunt.






Patients who died during the index admission or had no follow-
up data after hospital discharge were excluded from the read-
mission analysis (n 5 53), leaving 204 patients for analysis. Of
these, 74 were readmitted to the hospital within 30 days,
resulting in an estimated 37% readmission rate (Figure 3a).
Readmissions were specifically for CDI in 12 patients, resulting
in an estimated 6.2% readmission rate. Patients without R-CDI
had a 30-day readmission rate of 32%. In univariable analysis
(Table 3), readmissions were associated with presence of severe
CDI, increased Charlson Comorbidity Index, increased MELD
score, and use of fluoroquinolones. The stepwise variable se-
lection process identified 2 variables independently associated
with 30-day readmission. A greater hazard of readmission was
found for patients with increased Charlson Comorbidity Index
(HR 1.12; 95% CI: 1.03–1.23) and higher MELD score (HR 1.04;
95% CI: 1.01–1.07).
Ninety-day mortality
Of the 257 patients, 53 died within 90 days (28 during the index
admission and 25 after discharge), leading to an estimated mor-
tality rate of 22.8% (Figure 3b). In those without R-CDI, 90-day
mortality was 20.8%. Death was associated with nonalcoholic
steatohepatitis etiology of cirrhosis, severe CDI, fulminant CDI,
treatment with vancomycin, increased Child–Pugh score, in-
creased MELD score, and intensive care (Table 3). In multivari-
able analysis, mortality was associated with cirrhosis etiology
(alcoholHR 2.67; 95%CI: 0.99–7.22; hepatitis CHR 1.34; 95%CI:
0.48–3.72; other etiology HR 3.31; 95% CI: 1.19–9.25; reference:
nonalcoholic steatohepatitis), increased Child–Pugh score (HR
1.24; 95% CI: 1.11–1.39) and intensive care (HR 5.47; 95% CI:
3.05–9.84).
DISCUSSION
This large cohort study of more than 200 patients is the first,
to our knowledge, to examine the incidence, risk factors, and
outcomes of CDI recurrence in patients with cirrhosis. The
incidence of R-CDI in this study was 11.9%, which is on the
low end of rates reported in other populations. In a landmark
randomized trial of CDI treatment, R-CDI occurred in 25% of
patients treated with vancomycin and in 15% of those treated
with fidaxomicin (20). Another large, population-based
study found an R-CDI incidence of 14% (21). A systematic
review of 33 studies found a median recurrence rate of 22%
(range 10%–50%) across different populations (22). Two
large retrospective studies also found R-CDI rates of 10%
(23,24). Differences between studies could be due to differ-
ences in R-CDI definitions (e.g., different time frames for
recurrence and requirements for repeat laboratory testing).
In this study, we used the guideline-based definition of
R-CDI, which might favor a lower estimate compared with
other, more liberal R-CDI definitions (14). Other reasons for
higher rates seen in other studies include the potential for
detection bias: patients followed up prospectively in a clinical
trial protocol might be more likely to report and seek treat-
ment for recurrent diarrhea. Notably, although other chronic
conditions (e.g., chronic kidney disease [CKD]) are known
risk factors of R-CDI (22,25), cirrhosis has not been associ-
ated with an increased risk of R-CDI (24,26).
We found that R-CDI is independently associated with an
increased comorbidity burden. This observation confirms similar
findings in multiple other studies in different populations
(22,23,27). In addition to the overall comorbidity index,
R-CDI has been associated with several individual comor-
bidities, including diabetes and most prominently, CKD
(24,25,28). Beyond CKD, the risk of R-CDI might be even
greater in those with end-stage renal disease (25). Although we
did not find a significant association with end-stage renal
disease, the rate of R-CDIwas numerically greater in this group
(29.3% vs 11.9%; P5 0.11); the lack of a significant association
might be related in part to the limited number of patients with
end-stage renal disease. Increased age has been found to be
a risk factor of R-CDI in multiple studies (22). We found an
association with age in univariable analysis but not in the
multivariable analysis. This finding is likely due to the in-
clusion of age as a component of the comorbidity index. Last,
in addition to its association with R-CDI, an increased
Charlson Comorbidity Index has also been associated with
other poor CDI outcomes, including disease severity (29) and
in our study, hospital readmission.
The other factor independently associated with R-CDI was
lactulose use. This finding was unexpected and contradicts
other data. Previous in vitro work showed that lactulose-
induced stool acidification suppresses fecal anaerobes, in
particular C. difficile (30). Furthermore, in a case–control
study by Agarwalla et al. (31), lactulose use was associated with
a reduced risk of initial CDI in hospitalized patients with
decompensated cirrhosis. This discrepancymight be explained
by important differences between this study and that by
Agarwalla et al.. First, the study by Agarwalla et al. examined
initial CDI, as opposed to R-CDI in our study. Different risk
factors for initial vs R-CDI have been shown in other pop-
ulations (32). Second, in the study by Agarwalla et al., patients
with CDI were less likely to have hepatic encephalopathy and
rifaximin use compared with patients with cirrhosis without
CDI. Although the protective effect of lactulose on CDI was
maintained after adjustment for rifaximin use, the authors
were unable to adjust for hepatic encephalopathy because of
the high correlation with rifaximin use. By contrast, we found
a trend toward increased R-CDI in those receiving rifaximin
(20.2% vs 9.3%; P5 0.06), consistent with findings from other
studies demonstrating increasing rifaximin-resistant strains of
CDI (33). Finally, lactulose use in our study might simply be
a surrogate marker of liver disease severity; Lactulose use was
associated with a greater Child–Pugh score, a higher MELD
score, and more frequent cirrhosis complications such as he-
patic encephalopathy, ascites, varices, and spontaneous bac-
terial peritonitis.
Antibiotics and proton pump inhibitors are well-known risk
factors of initial CDI and R-CDI, but neither was associated
with R-CDI in our study. This finding might be due to wide-
spread use of thesemedications in this population, whichmight
have predisposed the patients in this cohort to develop CDI in
the first place. Notably, the proportion of patients receiving
either proton pump inhibitors or antibiotics did not decrease
on hospital discharge compared with admission. Improving
medication stewardship should remain a primary goal in the
effort to reduce R-CDI in cirrhosis.
In addition to R-CDI, we examined other patient outcomes
including hospital readmission and mortality. Our 90-day mor-
tality (22.8%) is lower than the mortality in another single-center
study (44% at 30 days) (34) but greater than the 13.8% in-hospital
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mortality seen in national inpatient data (13). Risk factors for
mortality in our study included increased Child–Pugh score and
intensive care, consistent with previous work (34). Thirty-day
readmissions occurred in 37% andwere associated with increased
MELD score and comorbidity burden. This rate is slightly higher
than the pooled readmission rate of 26% across different studies
of patients with cirrhosis (35), consistent with findings that
patients with cirrhosis and CDI have worse outcomes compared
with those of patients with cirrhosis without CDI (after control-
ling for age, comorbidities, cirrhosis complications, and other
infections) (13). Notably, MELD score is a well-established risk
factor of readmission in patients with cirrhosis (35).
We acknowledge several potential limitations to this study. Its
retrospective design makes it vulnerable to information biases.
We minimized any potential for such error through rigorous
standardized data abstraction to ensure consistency across the
study subjects. Furthermore, any misclassification is likely to be
nondifferential, which would bias findings toward the null.
Indiana University Hospital is a tertiary referral center, and the
study cohort might not reflect the larger population of patients
with cirrhosis and CDI. In addition, R-CDI could bemisclassified
if patients do not receive care for the recurrence at our center.
However, most patients with end-stage liver disease obtain their
care at referral centers, and they are more likely to return for
treatment of recurrence if the initial CDIwas treated at our center.
Finally, nearly half of the cohort was treated with metronidazole
monotherapy, which is no longer recommended for treatment of
initial CDI in recently published practice guidelines (14). How-
ever, R-CDI rates in our study were no different in those who
received vancomycin vs metronidazole alone, suggesting that our
observed risk factors for R-CDI are likely to be relevant in the
new, current treatment paradigm. Our study benefits from a large
sample size compared with previous studies, with detailed phe-
notyping of both liver disease and CDI characteristics. However,
the relatively low rate of R-CDI likely limits our power to identify
specific risk factors.
In conclusions, we found a rate of R-CDI in patients with
cirrhosis of 11.9%, exacerbated by a high comorbidity burden and
the use of lactulose. Patients with these risk factors might benefit
from interventions to prevent recurrent disease and improve
patient outcomes. Careful attention to medication usage should
remain a focus of these efforts.
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Study Highlights
WHAT IS KNOWN
3 CDI is common in patients with cirrhosis and is associated
with poor outcomes.
3 Patients with cirrhosis have high rates of hospitalization and
increased exposure to antibiotics and proton pump inhibitors,
which are known risk factors of CDI.
WHAT IS NEW HERE
3 The incidence of R-CDI in patients with cirrhosis is similar to
the incidence in other populations.
3 Risk factors of R-CDI in patients with cirrhosis include
increased comorbidity burden and the use of lactulose.
TRANSLATIONAL IMPACT
3 High-risk patients with cirrhosis and CDI might benefit from
interventions to prevent R-CDI.
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